header logo image


Page 830«..1020..829830831832..840850..»

108-Year-Old Woman Says Champagne Is the Key to Long Life – Thrillist

November 3rd, 2019 12:47 am

108 Year Old UK Woman Says Champagne is the Secret for Longevity - Thrillist

While you're off chugging green juice and pounding kale chips like they'rerealchips, I'll be over here drinking champagne. Because according to Dorothy Flowers, a lively and thriving 108-year-old, bubbly is the key to a long life.

Flowers, who resides at the Bupa Southlands nursing home in northern England, celebrated the big 1-0-8 with a bottle of Mot, aka her go-to, on October 22. "Dorothy loves company, so she'll sit with us at the reception desk each day," Resident Experience Manager Helene Ballinger toldMetro."Her real secret for longevity though has to be champagne. It's the only thing we ever see her finish a glass of. Needless to say, we've been toasting her birthday."

Recommended Video

Although she now struggles to speak, that hasn't kept her from charming everyone -- even fans across the world.

"While she's very independent, she's always been happiest when surrounded by others," her niece, Judith Barrett added. The outlet reports that Flowers received a flood of cards (nearly 700!) and plenty of goodies like gin, flowers, chocolates, and naturally, champagne.

"I'm lucky to have made many happy memories during my life and -- even at 108 -- I'm still making more," Flowers reportedly said with assistance from her caretaker.

She's also not the first person to have such a...creativetheory for her longevity. In 2017, a 109-year-old namedRuth Benjamin swore up and down that bacon was, in fact, the answer. So I guess I'll just incorporate both into my diet?

h/t Food & Wine

Sign up here for our daily Thrillist email and subscribe here for our YouTube channel to get your fix of the best in food/drink/fun.

Megan Schaltegger is a staff writer at Thrillist. Follow her @MegSchaltegger.

Like us on Facebook to get the best of both worlds.

We see that you already have an account. You're good to go!

There was an error signing up. Try again.

Our best stories, delivered daily

The best decision you'll make all day.

Read the original post:
108-Year-Old Woman Says Champagne Is the Key to Long Life - Thrillist

Read More...

Project management cell to assess health of bridges, ensure longevity – The Hindu

November 3rd, 2019 12:47 am

R&B Minister V. Prashanth Reddy said that the State government will extend its cooperation in setting up a new Project Management Cell which should ensure that the structures that are planned for 100 years will last longer.

He was speaking at the inaugural ceremony of the workshop on Health Assessment of Bridges and Structures organised jointly by the Institute of Engineers (India) Telangana State Centre and Construction Industry Development Council, New Delhi and Telangana government at the Institute of Engineers here on Saturday.

Appreciating the R&B department and CIDC for organising the workshop with the objective of checking the health of bridges, he said after the formation of Telangana in 2014, Chief Minister K. Chandrasekhar Rao allocated 12,000 crore for the development of road connectivity network. District connectivity and widening of single road into double roads, construction of bridges were taken up and the role of the R&B engineers in developing road network in the State was laudable, he said. But due to flooding of roads by overflowing causeways during rains, unless a high-level bridge was constructed, the roads would not be of use.

When the issue was taken to the notice of Chief Minister, he sanctioned 2,495 crore for construction of 511 bridges recognising the fact that there were more level causeways in Telangana. So far 400 bridges were completed at a cost of 1,700 crore and the remaining bridges were in progress. Latest technology was being used for the construction of bridges. In Hyderabad, Karimnagar cable stair bridge technology was being used. Along with bridges, check dams were also being constructed in the State. Check dams would be constructed in 184 locations and it would not only help in road connectivity but also save in conservation of rain water and improve water table.

The Minister felicitated several engineers on the occasion. President of Institute of Engineers Rameswara Rao and R&B Engineers in Chief Ravinder Rao and Ganapathi Reddy participated.

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Here is the original post:
Project management cell to assess health of bridges, ensure longevity - The Hindu

Read More...

Fidelity: Fixed Income Exciting In The Longevity Economy – finews.asia

November 3rd, 2019 12:47 am

Page 1 of 2

Investing for retirement requires investors to apply a consistent investment process, just like sticking to a diet and certain processes, said Fidelity International's Luc Froehlich.

A person looking to improve his fitness level would need to go on a diet, balance exercise, and nutrition, as well as use new forms of technology. Likewise, a person looking to build a healthy retirement portfolio would need to follow similar principles, said Luc Froehlich, global head of Investment Directing (Fixed Income) at Fidelity International,who was speaking at the firm's investment conference: How to capitalize on the Longevity Economy.

I tried low carb diet, paleo, keto...but my weight kept moving swinging up and down. (Finally), instead of going cold turkey on certain foods, I took small steps, in a consistent way, he said, proudly announcing that his newfound weight is now more stable.

Sticking to the Diet

In a similar manner, a healthy retirement portfolio should not experience too much volatility, as it serves an important role in funding the bulk of one's living expenses when he or she is no longer actively working, said Roehlich. Hence, the portfolio has to balance income generation with stability.

The second key success factor is sticking to the diet staying in the market. For decades now, it's beenproven that humans tend to be overconfident. We think we can do more than what we actually can. It is the same in investing. And one of the aspects in showing overconfidence is in investors thinking they can stomach more volatility than they actually can.

Throwing Up When Markets Turn

Due to this overconfidence, investors tend to build a portfolio with lots of equity, and they buy even more equities when their prices go up.

And then what happens?Market correction and risk assets are off. What do investors do? They are (now) more confident they cannot actually stomach this volatility and they sell at the worst time in the market.

How to Stay in the Market?

To help investors stay longer in the market,Froehlich advocates more allocation to fixed income assets. Although the use of fixed income to diversify one's investment portfolio is more widely understood, not many investors in Asia use the instrument for that purpose, he said.

In the past few years, fixed income has had equity-like returns. In Asia, a lot of investors are only using fixed income in the leverage business. So I think a lot of investors have forgotten the role of fixed income, which is simply to diversify a portfolio, he added.

Extending Portfolio Longevity

Whether one is taking a career break, or retiring, fixed income can be used to increase portfolio longevity, in line with a longer lifespan.When one has reached retirement years and sees no income, one needs the portfolio to provide income generation and total return.

Excerpt from:
Fidelity: Fixed Income Exciting In The Longevity Economy - finews.asia

Read More...

108-Year-Old Claims Champagne Is the Secret to a Long, Happy Life – Maxim

November 3rd, 2019 12:47 am

Photo: Getty Images

As we age, it sometimes feels like it's just a process of giving up fun stuff: Eating bad food, dialing back certain types of activity due to aches and pains, cutting down on or giving up drinking. Does it have to be? At least one senior citizen in the U.K. would likely say no.

In a HuffPost UK report on Dorothy Flowers, who turned 108 on October 22, her caretakers revealed she is a stalwart fan of champagne and chocolate and still just living as well as she is able.

More from HuffPost:

And, as for her secret to living well past 100? Dorothy believes its all about the chocolate and champagne.

Discussing the latter, the care homes Helene Ballinger said: "Its the only thing we ever see her finish a glass of. Needless to say, weve been toasting her birthday no one said life in a care home had to be boring."

Dorothy Flowers joins something of a chorus of elderswho are unapologetic consumers of what some would call vices.

Then again, there have been legit studies that say alcohol, coffee, and being overweight (at least a little) could aid longevity.

So skip that trip to the gym and grab a beer. Seems like you don't always need to live in self-denial to have a long, happy life.

See the original post:
108-Year-Old Claims Champagne Is the Secret to a Long, Happy Life - Maxim

Read More...

Saanich councillor gives keynote address at healthy aging conference in Japan – Victoria News

November 3rd, 2019 12:47 am

Saanich success as an age-friendly city was highlighted at an international healthy-aging conference in Japan in October.

Coun. Judy Brownoff was invited to give the keynote speech at the ninth annual World Health Capital Conference in Matsumoto, Japan. The conference took place on Oct. 16 and 17 and focused on the theme of Food and Exercises: Healthy Connections with Everyone.

READ ALSO: Saanich improves recreational opportunities for older adults

The conference touched on health and longevity views from around the world and Brownoff was asked to share the work that Saanich has been doing to engage aging residents and help them lead healthy lives.

In her presentation, Brownoff explained that in 2006, Saanich joined the World Health Organizations Age-Friendly Communities initiative and has since been working to implement services that will help older residents enjoy healthy, active lives.

Akira Sugenoya, the mayor of Matsumoto, said there were a lot of good ideas to take away from Brownoffs presentation as his city encourages residents to take an active role in their own longevity.

The conference featured panels and discussions on various topics from health promotion in Russia to a physiotherapy device designed for folks with arthritic in their hands.

Events such as these help cities around the world share ideas about healthy longevity and learn from one another, said Hiroyuki Kobayashi, director of health industry in Matsumoto.

READ ALSO: NEAT program aims to socialize isolated seniors

Brownoff agreed and noted that sharing ideas in this way helps to plan for aging populations to continue to live engaged, active lives.

Many cities in the world are experiencing longevity in older adults and there are many opportunities for active and creative aging, said Brownoff.

Brownoff has a background in age-friendly communities as she serves as co-chair of the Public Health Agency of Canada of the Pan Canadian Age-Friendly Communities Reference Group a group with representatives across Canada that meet once a month to discuss the problems facing older adults.

@devonscarlettLike us on Facebook and follow us on Twitter.

devon.bidal@saanichnews.com

Visit link:
Saanich councillor gives keynote address at healthy aging conference in Japan - Victoria News

Read More...

If I Could Buy Only 1 Stock, This Would Be It – Motley Fool

November 3rd, 2019 12:47 am

I carry a total of 23 tickers in my personal investment portfolio. The two largest holdings in it are streaming video giant Netflix (NASDAQ:NFLX) and e-commerce veteran Amazon.com (NASDAQ:AMZN) Both of these stocks have treated me very well over the years, and they happen to be great buys in today's market as well. These tickers will probably stay with me until I stop investing or the mullet becomes fashionable again, whichever comes first. (Hint: Trendy mullets are more likely than for me to hang up my Wall Street spurs.)

But if I had to liquidate it all and select just one stock for the long haul, I would actually go in a different direction. The only stock I would trust to meet all my investment needs forever is actually Google and Android parent Alphabet (NASDAQ:GOOG) (NASDAQ:GOOGL).

Alphabet is my idea of a centennial investment.

I mean, bothGeneral Electric (NYSE:GE) and IBM (NYSE:IBM) have stuck around for a hundred years by constantly adapting to ever-changing market conditions. They survived technological revolutions, world wars, and lots of pitch-black recessions by ending business operations that no longer worked and replacing them with ideas better suited to the next challenge.

The keyword here is flexibility. GE and IBM have always had it in spades. Alphabet is no different.

Image source: Getty Images.

The company we now know as Alphabet used to be a one-trick pony. Sure, Google's online search and advertising empire is a pretty great trick, but the time will come when those operations just won't keep the lights on anymore.

Never afraid to tackle new business ideas -- big bets with uncertain outcomes such as the YouTube short-form video platform and the Android mobile phone system spring to mind -- the company rebranded itself as a collection of very diverse operations. It's true that Google-branded businesses accounted for 99.6% of Alphabet's total sales in the third quarter and all of the operating profits, but you have to start somewhere.

Alphabet is alpha-betting on a wide variety of mostly offline operations, from self-driving cars and medical research to drone-based delivery services and energy storage based on large tanks of molten salt. None of them are pulling their weight from a financial point of view, but some analysts expect the Waymo self-driving car service to become a $100 billion business in its own right, roughly a decade from now.

Most of Alphabet's non-Google stuff will probably fail to make a difference in the long run, but it is important that the company is exploring a plethora of new ideas at all times. One or two game-changing wins per decade should be plenty to keep Alphabet relevant, competitive, and profitable, effectively forever from the vantage point of one middle-aged human.

There you have it. If I had to pick a single stock to power my portfolio all by itself for years and decades to come, Alphabet would be it. It's already a very large business but I'm convinced that we ain't seen nothin' yet.

I almost feel like I'm cheating a little because this single stock works as a play on lots and lots of different business ideas -- many of which we haven't even imagined yet. Alphabet's best days lie ahead, and we might even forget all about the ancient Google roots when all is said and done.

And that would be fine by me.

More here:
If I Could Buy Only 1 Stock, This Would Be It - Motley Fool

Read More...

In June, FDA announced a patient died from a fecal transplant. Now the doctors are speaking out. – The Daily Briefing

November 3rd, 2019 12:46 am

Doctors from the hospital that treated a patient who died after a fecal microbiota transplant published a case study on Wednesday in the New England Journal of Medicine that offers more details on the case as well as another case in which a patient became severely ill from the procedure.

How to eradicate antibiotic overuse

FDA announced in June that it had become aware that patients who undergo FMT can experience severe or life-threatening bacterial infections caused by drug-resistant bacteria. FDA said two patients with weakened immune systems who received FMT developed infections stemming from extended-spectrum-beta-lactamase (ESBL) producing E. coli, which is resistant to antibiotics. FDA reported that one of those patients had died.

FDA said both FMTs involved stool from the same donor. The donor's stool had not been tested for ESBL-producing gram-negative organisms before the providers conducted the transplants, according to FDA.

FDA said the donor's stool underwent lab tests after the two patients experienced adverse reactions, and the tests confirmed the stored stool contained ESBL-producingE. coliidentical to the bacteria found in stool used in the two transplants.

As a result of the developments, FDA issued new safety guidelines for FMTs, saying it would now require FMTs to involve:

FDA did not provide many details on the two cases, which led doctors from Massachusetts General Hospital, where the patients were treated, to issue a report detailing the cases. Elizabeth Hohmann, co-author of the report and associate professor of medicine and infectious diseases at Mass General and Harvard Medical School, said, "We wanted to set the record straight."

According to the report, both patients were involved in clinical trials to see if FMTs could be used as a potential therapy for their conditions. One patient was in a trial to learn whether FMTs could help improve brain function in patients with severe liver disease. The other was participating in a trial to see if FMTs could be used to help immune function in leukemia patients who had undergone chemotherapy and stem cell transplants.

Two and a half weeks after doctors administered the final FMT dose to the liver disease patient, a form of E. coli was found in the patient's bloodstream, the report said. The patient recovered after intravenous antibiotics killed the bacteria.

The leukemia patient also developed the same form of drug-resistant E. coli. However, the patient had taken drugs to suppress his immune system as part of a bone marrow transplant and began to decline faster, the report said. Eight days after his last FMT dose, the patient was placed on a ventilator, and two days later the patient died from a severe bloodstream infection, according to the report.

Upon investigation of the liver patient's infection, doctors discovered that the stool sample used for the FMT contained the drug-resistant organism.

According to Hohmann, the stool donor was "what I call a 'screamingly healthy person.' Only about one in 40 people who think they might be healthy enough to [donate stool] actually turn out to meet all of our criteria. [The donor] had none of the 'risk factors' for carrying these organisms. They could not recall the last time they received antibiotics, had zero medical history, no international travel. Plus, they completed all of the other screening tests."

The doctors had been following FDA protocol testing stool donations for infectious bugs, but were not instructed by FDA to test or destroy older stool samples kept in storage, Hohmann said. The stool sample that sickened the two patients in the report had been stored in a freezer for several months.

"It wasn't obvious to a lot of smart people here," Hohmann said. "We didn't think to go back in time."

Hohmann said the report should serve as "a cautionary and sad tale. It points out some of the important medical issues about immune-compromised [patients] and maybe that changing the microbiome is not always a good idea."

Alexander Khoruts, a professor of medicine and medical director of the Microbiota Therapeutics Program at the University of Minnesota who was not involved in the report, said the report should "set off alarm bells for those who thought that [FMTs were] risk free." He added that Mass General "did the right thing" by sharing details and that he hopes the report will lead doctors to be more cautious.

Stuart Johnson, an associate professor of medicine at Loyola University Stritch School of Medicine, who specializes in the bacterial gut infection Clostridium difficile, said he thinks the report "points out that we don't know everything that's in someone's feces, and I think widespread adoption of this practice is problematic" (Carroll, NBC News, 10/30; Jacobs, New York Times, 10/30; Smith, Medium, 10/30).

Read more:
In June, FDA announced a patient died from a fecal transplant. Now the doctors are speaking out. - The Daily Briefing

Read More...

Merck Announces Third-Quarter 2019 Financial Results – Business Wire

November 3rd, 2019 12:45 am

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2019.

We achieved another quarter of strong revenue and earnings growth as we continue to realize the benefits of our sustained investment in research and development and our focus on commercial execution, said Kenneth C. Frazier, chairman and chief executive officer, Merck. We are confident that the investments we are making now will allow us to convert cutting-edge science into medicines and vaccines of great benefit to patients and value to shareholders.

Financial Summary

$ in millions, except EPS amounts

Third Quarter

2019

2018

Change

ChangeEx-Exchange

Sales

$12,397

$10,794

15%

16%

GAAP net income1

1,901

1,950

-3%

-3%

Non-GAAP net income that excludes certain items1,2*

3,873

3,178

22%

22%

GAAP EPS

0.74

0.73

1%

1%

Non-GAAP EPS that excludes certain items2*

1.51

1.19

27%

27%

*Refer to table on page 9

GAAP (generally accepted accounting principles) earnings per share assuming dilution (EPS) were $0.74 for the third quarter of 2019. Non-GAAP EPS of $1.51 for the third quarter of 2019 excludes a $982 million charge for the acquisition of Peloton Therapeutics, Inc. (Peloton), a $612 million pretax intangible asset impairment charge, other acquisition- and divestiture-related costs, restructuring costs and certain other items. Year-to-date results can be found in the attached tables.

Pipeline Highlights

Oncology

Merck continued to advance the development programs for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy; Lynparza (olaparib), a PARP inhibitor being co-developed and co-commercialized with AstraZeneca; and Lenvima (lenvatinib mesylate), an orally available tyrosine kinase inhibitor being co-developed and co-commercialized with Eisai Co., Ltd. (Eisai).

KEYTRUDA

Lynparza

Lenvima

Other Pipeline Highlights

Third-Quarter Revenue Performance

The following table reflects sales of the companys top pharmaceutical products, as well as sales of animal health products.

Third Quarter

2019

2018

Change

Change Ex-Exchange

Total Sales

$12,397

$10,794

15%

16%

Pharmaceutical

11,095

9,658

15%

16%

KEYTRUDA

3,070

1,889

62%

64%

GARDASIL / GARDASIL 9

1,320

1,048

26%

27%

JANUVIA / JANUMET

1,311

1,490

-12%

-11%

PROQUAD, M-M-R II and

VARIVAX

623

525

19%

19%

BRIDION

284

217

31%

32%

ISENTRESS / ISENTRESS HD

250

See more here:
Merck Announces Third-Quarter 2019 Financial Results - Business Wire

Read More...

MEMS for Therapeutic Market Size, Share Analysis by Services, Technique, Design and Application Forecast by 2023 – Health News Office

November 3rd, 2019 12:45 am

The analysis and research team at TMR enables customization of report for any market study. Our experienced research analysts will understand your exact business requirement and provide the most pertinent report for competitive gains.

Overview

The market intelligence report from TMR is a valuable tool that enables vendors to identify growth avenues, and strategize for launch of products and services. These findings help businesses pave way in a crowded business landscape, and make way into the future with confidence.

To provide this, analysts carried out a succinct analysis of demand drivers, restraints, opportunities, and threats that are likely to influence the Cervical Cancer Therapeutics market over the Cervical Cancer Therapeutics forecast period. These market indicators serve valuable for market stakeholders for business planning, scope of expansion, financial modeling, investment proposition, and to understand competitive dynamics in the Cervical Cancer Therapeutics market over the forecast period.

Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40796&source=atm

The market research report on Cervical Cancer Therapeutics also offers valuable insights into key business strategies employed by established players, along with impact of these strategies on future business landscape.

Market segments and sub-segments

The regional analysis covers:

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

The study is a source of reliable data on:

Request For Discount On This Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40796&source=atm

The regional analysis covers:

The analysis of a market presented in our reports provides valuable insights for strategic planning for businesses to obtain competitive advantage. Included in our research reports are valuable projections to understand market share that key players might hold in the future.

The report includes SWOT analysis of key players, which shall be a crucial market intelligence for mergers, acquisitions, collaborations, or partnerships between market stakeholders. In addition, the report carries out robust groundwork for inclusion of market segmentation by type, application, and geography. This helps market stakeholders gauge the best bet to make investments in the Cervical Cancer Therapeutics market over the Cervical Cancer Therapeutics forecast period.

Highlights of the report:

RequestTOC For ThisReport @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=40796&source=atm

Key Questions Answered in the Cervical Cancer Therapeutics Report

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The companys exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMRs experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact

Mr. Rohit BhiseyTransparency Market ResearchState Tower90 State Street,Suite 700,Albany, NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email: [emailprotected]Website: http://www.transparencymarketresearch.com

Read the rest here:
MEMS for Therapeutic Market Size, Share Analysis by Services, Technique, Design and Application Forecast by 2023 - Health News Office

Read More...

Merus (NASDAQ:MRUS) Stock Rating Lowered by Zacks Investment Research – Polson News

November 3rd, 2019 12:45 am

Zacks Investment Research cut shares of Merus (NASDAQ:MRUS) from a hold rating to a sell rating in a research report report published on Friday morning, Zacks.com reports.

According to Zacks, Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The companys bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.

MRUS has been the subject of a number of other reports. ValuEngine upgraded Merus from a sell rating to a hold rating in a research note on Thursday. BidaskClub upgraded Merus from a hold rating to a buy rating in a research note on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the companys stock. The company presently has an average rating of Buy and an average price target of $23.43.

Shares of MRUS traded up $0.33 during trading hours on Friday, hitting $15.99. The stock had a trading volume of 102,700 shares, compared to its average volume of 91,051. The companys fifty day simple moving average is $17.16 and its 200 day simple moving average is $15.58. The firm has a market cap of $335.80 million, a P/E ratio of -8.69 and a beta of 0.24. Merus has a 12-month low of $11.00 and a 12-month high of $20.95.

Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Monday, August 19th. The biotechnology company reported ($0.57) EPS for the quarter, missing the Zacks consensus estimate of ($0.54) by ($0.03). The firm had revenue of $6.27 million during the quarter, compared to analyst estimates of $8.62 million. Merus had a negative return on equity of 41.68% and a negative net margin of 104.10%. As a group, sell-side analysts expect that Merus will post -1.74 EPS for the current year.

A number of large investors have recently bought and sold shares of the stock. Artal Group S.A. grew its stake in Merus by 16.7% in the second quarter. Artal Group S.A. now owns 350,000 shares of the biotechnology companys stock worth $5,128,000 after purchasing an additional 50,000 shares in the last quarter. Morgan Stanley lifted its holdings in Merus by 3.1% in the second quarter. Morgan Stanley now owns 92,776 shares of the biotechnology companys stock worth $1,359,000 after acquiring an additional 2,788 shares during the last quarter. Athanor Capital LP bought a new position in Merus in the second quarter worth about $334,000. Finally, JPMorgan Chase & Co. lifted its holdings in Merus by 63.5% in the second quarter. JPMorgan Chase & Co. now owns 8,722 shares of the biotechnology companys stock worth $123,000 after acquiring an additional 3,389 shares during the last quarter. Institutional investors and hedge funds own 52.00% of the companys stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Read More: Do You Need a Fiduciary?

Get a free copy of the Zacks research report on Merus (MRUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

See the original post:
Merus (NASDAQ:MRUS) Stock Rating Lowered by Zacks Investment Research - Polson News

Read More...

AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November – PRNewswire

November 3rd, 2019 12:45 am

IRVINE, Calif., Nov. 1, 2019 /PRNewswire/ --AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that it will be presenting at the following regenerative medicine and investor conferences in November:

Society for the Immunotherapy of Cancer (SITC) Annual MeetingOral PresentationPresenter: Dr. Daniela Bota, MD, PhD, University of California, Irvine; AIVITA GBM Principal InvestigatorTitle: Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastomaTime: November 6-10, 2019Location: Gaylord National Hotel & Convention Center, National Harbor, MD

The Regenerative Medicine Consortium of the Gulf Coast Consortia for Biomedical SciencesOral Presentation Presenter: Dr. Hans S. Keirstead, AIVITA Chairman and CEOTitle: Clinical and Commercial Application of Scaled Human Stem Cell DerivatesTime: November 8, 4:00 PM CTLocation: Bioscience Research Collaborative, Houston, TX

NYC Oncology Investor ConferenceOral Presentation Presenter: Dr. Hans S. Keirstead, AIVITA Chairman and CEO Title: AIVITA Corporate PresentationTime: November 12, 4:50 PM - 5:10 PMLocation: Rockefeller Center, New York, NY

Society for NeuroOncology Annual MeetingPoster PresentationTitle: Phase II trial of AV-GBM-1 (autologous dendritic cells loaded with autologous tumor associated antigens) as adjunctive therapy following primary surgery plus concurrent chemoradiation in patients with newly diagnosed glioblastoma.Time: November 20-24, 2019Location: JW Marriott Desert Ridge, Phoenix, AZ

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. All proceeds from the sale of AIVITA's skin care products support the treatment of women with ovarian cancer.

SOURCE AIVITA Biomedical, Inc.

Homepage

See original here:
AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November - PRNewswire

Read More...

Thought Leadership & Innovation Foundation to Expand Its Regenerative Medicine Program Through New Collaboration with RenovaCare – Business Wire

November 3rd, 2019 12:45 am

MCLEAN, Va.--(BUSINESS WIRE)--The Thought Leadership & Innovation Foundation (TLI) announces today plans to build on its existing Regenerative Medicine Program through a research collaboration with cellular therapy industry leader RenovaCare. As part of TLIs efforts to conduct vital research in regenerative medicine and chronic disease, this initiative aims to innovate methods for reducing complications from burn and diabetic wounds across large populations.

Our research base, collaborative institutions and long history of innovation align with RenovaCares commitment to breakthrough biomedical technologies, says Bill Oldham, founder and chairman of the Board, TLI. The patented RenovaCare SkinGun technology and its ability to ultra-gently spray stem cells could present a special opportunity for investigations and applications in a wide range of regenerative therapies. Working together, our overall goal is to improve the quality, efficiency and effectiveness of patient care by not only developing new treatment methods, but also by making thoughtful and systematic changes to healthcare and health systems.

TLIs Regenerative Medicine program seeks to adapt new strategies based upon sound scientific evidence, utilizing its infrastructure to support the continuation of scientific and medical work, as well as the development of grant-funded research and other initiatives.

Dr. Robin A. Robinson, who is a TLI Fellow, Vice President of Scientific Affairs, RenovaCare, and named one of the top 100 innovators in medicine by Medicine Maker in 2018, states, This exciting collaboration between RenovaCare and TLIs Regenerative Medicine Program is the first step toward the development of meaningful and quality therapeutic treatments that will benefit patients around the world.

About TLI Foundation:

TLI Foundation is a nonprofit foundation focused on driving innovative thinking and action on global issues relating to health, education and economic empowerment. The organization is committed to fostering transformative change and improving the health and well-being outcomes of communities around the world. Visit https://www.thoughtfoundation.org/

About RenovaCare:

RenovaCare, Inc. is a biotechnology company focused on developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Initial products under development target the bodys largest organ, the skin. Investigative clinical use of their flagship technology has shown to be promising new alternatives for patients suffering from burns, and chronic and acute wounds. https://www.renovacareinc.com.

Originally posted here:
Thought Leadership & Innovation Foundation to Expand Its Regenerative Medicine Program Through New Collaboration with RenovaCare - Business Wire

Read More...

New Alzheimer Treatment Could Take The Brakes Off The Bodys Repair Systems Allowing It To Repair Itself – Forbes

November 3rd, 2019 12:45 am

A regenerative medicine company in Vancouver, British Columbia will begin Phase 1 studies in early 2020 for a treatment for nerve damage and degenerative diseases including Alzheimers disease.

NervGen Pharma wants to advance its proprietary therapeutic technology platform, currently in development for spinal cord injury and multiple sclerosis (MS), to generate new treatments for Alzheimer's disease.

The essence of our technology is that it takes the brakes off the bodys repair systems and allows the nervous system to repair itself, said Bill Radvak, the companys executive chairman and co-founder. You can think of it as the bodys nervous system has a housekeeping function that is constantly at work, fixing bad connections with new ones and tidying up redundant ones.

Digital

In a nutshell, the body produces a scar at sites of physical injury such as a spinal cord injury as well as sites of inflammatory damage from neurodegenerative diseases such as multiple sclerosis and Alzheimer's disease. The purpose of the scar is to encapsulate the site of the injury to prevent further damage but it ultimately inhibits the body's reparative mechanisms.

The co-inventor of NervGen's technology, Dr. Jerry Silver, Professor of Neurosciences at Case Western Reserve University's School of Medicine in Cleveland, Ohio, discovered that a component of these scars, a protein called CSPG, inhibits the body's natural ability to regrow and regenerate. NervGen's technology platform removes this inhibition and, via multiple endogenous repair mechanisms, unlocks the nervous system's ability to repair itself in a manner adapted to the site of injury and type of disease, Radvak said. Numerous repair mechanisms, including regeneration, plasticity and remyelination, have been observed in the various animal models such as stroke, spinal cord injury, multiple sclerosis, cardiac arrhythmia and peripheral nerve injury as reported in over a dozen peer reviewed papers.

In the injured state, the new nerves get stuck because the amount of CSPGs increase, and they bind to a receptor called PTPsigma, which is found on nerves, pinning them in place, Radvak explained.

NervGens core technology targets the protein tyrosine phosphatase sigma (PTP), a neural receptor that impedes nerve regeneration. Inhibition of this receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for various medical conditions, Radvak said.

NervGen has identified a series of receptor antagonistsdrugs that block or dampen biological response by binding to and blocking a receptor rather than activating it (think beta blockers)including its lead candidate, dubbed the NVG-291 compound, that they say is ready for clinical development. NervGen has been studying the compound to treat spinal cord injury. Now they want to identify other diseases for its use, including Alzheimers.

Our molecules unstick nerves and prevent new ones from getting stuck, he said. This same receptor, PTPsigma, is also found on myelin, or to be more scientifically correct, on OPCs [Oligodendrocyte progenitor cells] which develop into myelin. So, our treatment allows the myelin, which is damaged in MS, to repair itself.

Radvak said NervGen is hopeful the treatment will work in Alzheimers due to the nature of the disease itself. You also find the same problem in Alzheimers diseaseCSPGs are found in the plaques associated with the disease. We are hoping that our treatments can help the body remove the plaques and then allow new nerve connections to regrow. If our theory is correct, we hope that this could one day prevent and even reverse the disease and its terrible effects.

Alzheimer's disease is a progressive neurodegenerative disorder that destroys memory and cognitive functions. Scientists and others estimate 30 million people are affected by the disease globally including 5.8 million in the United States alone. Experts say, by 2025, the number of seniors with Alzheimer's disease could reach 7.1 million, and the prevalence of Alzheimer's disease could reach 13.8 million by 2050. The estimated cost in 2019 of caring for Americans with Alzheimer's disease and other dementias is $277 billion, a number that does not include unpaid caregiving. Of that amount, $186 billion is the cost to Medicare and Medicaid, and $60 billion is for out-of-pocket costs. Alzheimer's disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disease may rank third, just behind heart disease and cancer, as a cause of death for seniors.

As Alzheimers research and development efforts have failed to produce new effective treatments in the last fifteen years, the medical community and pharmaceutical industry are seeking technologies with new approaches through new targets and pathways.

For example, earlier this year drug companies, Biogen and Eisai, announced they were scrapping two phase 3 trials of the investigational anti-amyloid agent aducanumab for Alzheimer's disease based on an interim futility analysis, Medscape reported this week, but in a surprising about-face, new data from the studies mean the drug is back on the table.

A statement released by the drug's manufacturers said a new analysis from the EMERGE trial shows that the drug actually met the primary endpoint of significant reduction in clinical decline, including cognition and function. In the ENGAGE trial, the cohort of patients who received a high dose of aducanumab support the findings from EMERGE, Medscape reported. They note that after consulting with the US Food and Drug Administration (FDA), regulatory approval for the drug is back on track and will be pursued.

"NervGen's platform technology introduces a truly novel approach to treating Alzheimer's disease," George Perry, PhD, said in a statement. Perry is the current editor-in-chief for the Journal of Alzheimer's Disease and professor of biology and Semmes Distinguished University Chair in neurobiology at the University of Texas at San Antonio.. "Work that began in the early 90s has confirmed the importance of the biological effect of proteoglycans in the central nervous system. In particular, the ability to shift microglia from the inflammatory phase to the phagocytic or housekeeping phase, as evidenced in both a spinal cord injury and multiple sclerosis model, is promising as it is the natural reparative process for removal of amyloid plaques. This demonstration of an immunomodulatory effect on the microglia will be of specific interest in the quest for a solution to Alzheimer's disease as the function of the microglia is one of the hot topics in this still evolving story."

Dr. Ernest Wong, NervGen's president and CEO said in a statement the Phase 1a study will be followed by a Phase 1b on subsets of both chronic and sub-acute spinal cord patients and a Phase 2 study on multiple sclerosis in 2021. Chondroitin sulfate proteoglycans (CSPGs} are intimately associated with senile plaques and our work with PTP knockout mice and other data with chondroitinase all suggest a pivotal role for PTP in AD, he said.

NervGen has taken this discovery into industrial development and is turning the platform into drugs to be developed, Radvak said. The NervGen programs are by far the most advancedwe are unaware of anyone else working with this approach. The company also has a number of patents which gives it exclusivity on this scientific approach. If we are successful and get the products to market, they would be a radically different treatment and first-in-class.

And though drug development takes time and several steps, Radvak said he is hopeful a treatment will be available soon. We are about to a big step by starting the first human trials, he said. The Company plans to submit an Investigational New Drug application with the U.S. Food and Drug Administration for NVG-291 with the intention of initiating a Phase 1 human clinical trial on healthy subjects in early 2020 and expansion of that trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, NervGen intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.

This process takes a number of years for the product to get to market but drug development is like a relay race, he continued. Smaller companies develop drugs in the early steps and often hand over to Pharma for late stage development. At this handover, the company or product is sold to the Pharma which has increased capabilities to commercialize.

More here:
New Alzheimer Treatment Could Take The Brakes Off The Bodys Repair Systems Allowing It To Repair Itself - Forbes

Read More...

Global Regenerative Medicine Market 2019 Worldwide Industry Analysis to 2024 – Top News Herald

November 3rd, 2019 12:45 am

Global Regenerative Medicine Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024 is the most important research for who looks for complete information about the Regenerative Medicine market. The report takes a critical look at the business regulatory framework, technological advances in associated industries, and strategic approaches. For market demand, size, trading, supply, competitors, and prices as well as global predominant vendors information, the report covers all information on the global and regional markets including old and future trends. The research study also explains upcoming industry supply, market demand, value, application, type, share, competition and its analysis of key players with industry forecast from 2019 to 2024.

The research report commits different factors affecting Regenerative Medicine industry such as past data and market trends, technological advancements, upcoming innovations, market risk factors, market restraints, and challenges in the industry. The study then describes the drivers and restraints for the market along with the impact they have on the demand over the forecast period. It also observes the latest trends and development plans, patterns, and policies observed in the global market.

DOWNLOAD FREE SAMPLE REPORT: https://marketandresearch.biz/sample-request/91858

This report includes the following top vendors in terms of company basic information, product category, sales (volume), revenue (Million USD), price and gross margin (%). They are: ABS Protection GmbH, Mammut, Clarus Corporation, Backcountry Access, Scott, Ortovox, ARVA, Osprey Packs, The North Face, Dakine, Mystery Ranch, Millet(Calida Group), Motorfist, Deuter,

On the basis of types, the market is primarily split into Mono Avalanche Airbags, Dual Avalanche Airbags

On the basis of applications, the market covers: Skiing, Climbing, Hiking, Others

On the basis of geography, the market covers: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

How Far Does The Scope of This Research Study Traverse?

ACCESS FULL REPORT: https://marketandresearch.biz/report/91858/global-regenerative-medicine-market-2019-by-manufacturers-regions-type-and-application-forecast-to-2024

Key Market Dynamics: The global Regenerative Medicine market research report forecasts the latest market trends, development methods, and research methodologies. Several factors that are directly affecting the market such as the strategic production and methods, development platforms, and the product model, as well as the minute change within the product profile, are included in the report.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketandresearch.biz), who will ensure that you get a report that suits your needs.

Ron is a very well known face in the journalism world. He is the editor-in-chief of Top News Herald. He covers Business news for Top News Herald. He lives in Buffalo New York with his wife Melinda.

See more here:
Global Regenerative Medicine Market 2019 Worldwide Industry Analysis to 2024 - Top News Herald

Read More...

BIOSTEM TECHNOLOGIES, INC. ANNOUNCES CORPORATE UPDATE; RESIGNATION OF CHAIRMAN AND CEO, APPOINTMENT OF INTERIM CEO AND CHARIMAN; BOARD INITIATES…

November 3rd, 2019 12:45 am

POMPANO BEACH, FL, Oct. 29, 2019 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC/PK:BSEM) today announced Henry Van Vurst would be stepping down as the company's Chief Executive Officer and as Chairman of the Board of Directors, effective October 22, 2019. Henry is yielding the position to focus on sales and business development for the companys life sciences division. The BioStem Board of Directors has elected Jason Matuszewski, a co-founder and longtime member of the executive team, as the company's interim Chief Executive Officer and Chairman, effective October 22, 2019.

"The Board of Directors of BioStem Technologies has accepted Henrys decision to step down as CEO and Chairman to focus on business development and sales, said Jason Matuszewski. Matuszewski continued, as one of the founders of BioStem Technologies, I have a profound commitment to the success of our company and to ensure the continual focus of our vision and the execution of our strategy. I am fully invested in reassuming the role of CEO until such a time that this important responsibility can be transitioned to the right person following a systematic search that will allow us to maintain our focus on our important fourth quarter.

The company also announced the expansion of its leadership team with the addition of Ken Warrington, PhD as Senior Vice President of Operations. Dr. Warrington brings significant expertise in biopharmaceutical product development and cGMP production. Dr. Warrington will play a key role in the expansion of the laboratory production and development initatives as BioStem continues to accelerate its growth of the BioStem Life Sciences division.

About BioStem Technologies, Inc.(OTC PINK: BSEM):BioStem Technologies, Inc.is a global life sciences corporation, providing innovative technologies with a concentration in Regenerative Medicine. The companys mission is to discover, develop and produce the most effective Regenerative Medicine products in the world. The company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.

BioStem Life Sciences, Inc.A company focused on the development of the highest quality birth tissue products for multiple sectors of healthcare. BioStem Life Sciences offers a comprehensive portfolio of high quality brands that include Rheo, Vendaje and Vendaje Optic. BioStem Life Sciences also provides leading class contract manfuactuing services to GMP and GTP standards for companies looking to develop birth tissue products, from bench top to comericalization. For the latest news and information about BioStem Life Sciences and its brands, please visitwww.biostemlifesciences.com

Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.

BioStem Technologies, Inc.Phone: 954-380-8342 Website: http://www.biostemtechnologies.com Email: info@biostemtech.comTwitter: @BiostemtechFacebook: BioStem Technologies

Investor Relations:Andrew Van Vurstinfo@biostemtech.com(954) 380-8342

The rest is here:
BIOSTEM TECHNOLOGIES, INC. ANNOUNCES CORPORATE UPDATE; RESIGNATION OF CHAIRMAN AND CEO, APPOINTMENT OF INTERIM CEO AND CHARIMAN; BOARD INITIATES...

Read More...

BioLife Solutions to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019 – Yahoo Finance

November 3rd, 2019 12:45 am

BOTHELL, Wash., Oct. 31, 2019 /PRNewswire/ --BioLife Solutions, Inc. (BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's third quarter 2019 financial results will be released after market close on Tuesday, November 12, 2019, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.

Cell and gene therapy tools. (PRNewsfoto/BioLife Solutions, Inc.)

To access the webcast, log on to the Investor Relations page of the BioLife Solutions website at http://www.biolifesolutions.com/earnings. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 7207519. A webcast replay will be available approximately two hours after the call and will be archived on http://www.biolifesolutions.com for 90 days.

About BioLife Solutions

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools. Our proprietary CryoStor freeze media and HypoThermosol shipping and storage media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our recently acquired ThawSTAR family of automated cell thawing products and evo cold chain management system reduce therapeutic and economic risk for cell and gene therapy developers by reducing the potential of administering a non-viable dose. For more information, please visit http://www.biolifesolutions.com and follow BioLife on Twitter.

View original content to download multimedia:http://www.prnewswire.com/news-releases/biolife-solutions-to-report-third-quarter-2019-financial-results-and-provide-business-update-on-november-12-2019-300949616.html

The rest is here:
BioLife Solutions to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019 - Yahoo Finance

Read More...

Stem Cell Therapy: What’s Real and What’s Not at California’s For-Profit Clinics – UCSF News Services

November 3rd, 2019 12:44 am

Many for-profit stem cell clinics advertise therapies that are not backed by science and may actually cause harm.

For-profit stem cell clinics have popped up around California in recent years, advertising that they can treat everything from arthritis to Alzheimers, without FDA approval.

They claim that injections of stem cells (naturally occurring blank slate cells that can grow into any type of cell) can help alleviate pain or illness by replacing or regenerating diseased tissue claims that are not supported by existing research. The procedures can cost thousands of dollars out-of-pocket, and regulators have warned that patients have developed tumors, suffered infections and even lost eyesight after unapproved procedures.

No one knows how many clinics there are, but California reportedly has more than any other state. We asked Arnold Kriegstein, MD, PhD, director of the UC San Francisco Developmental & Stem Cell Biology Program, about whats real and whats not in stem cell medicine.

How do these clinics operate?

There has been an explosion of so-called clinics offering stem cell treatments for a wide range of ailments, none of which have been shown to be effective. They are largely unregulated. Many clinics claim that they can treat untreatable illnesses like Alzheimer's disease, autism, muscular dystrophy, or stroke. The list is quite extensive.

The majority are using fat tissue for their stem cells, obtained through liposuction. These are usually autologous cells, which means that they are taking the patient's own tissue and extracting cells to re-administer to the same patient, usually through an intravenous route. In addition to fat cells, some clinics administer bone marrow stem cells or umbilical cord or placental stem cells, which come from unrelated donors.

The clinics often advertise through testimonials from patients who've received their therapies. Many of the conditions that the testimonials address are the kinds that normally improve or fluctuate over time, such as joint pain, low back pain, arthritis, or multiple sclerosis.

The problem is that patients will receive a treatment, and then, within a month or two, they'll notice that the aches and pains in the joints are improving, and they will attribute the improvement to the stem cell therapy, when in fact it would've happened regardless.

What is the risk of trying an unproven stem cell treatment?

Reports of physical harm have included infections and the development of tumors. When using cells that are not the patients own, umbilical cord cells for example, immune responses can occur often triggering inflammatory conditions.

In cases where stem cells have been delivered into the eye, blindness has been reported, and when they have been delivered to the central nervous system through lumbar puncture (spinal tap), adverse outcomes including serious infections of the central nervous system and tumors have occurred.

Then there's the emotional cost associated with raising false hope, and the financial loss that comes from exorbitant fees charged for ineffective, potentially harmful therapies.

Why arent there more legitimate stem cell therapies available?

Stem cells have been in the news so much over the last decade or so that I think it has created the impression that therapies are already on the market. The reality is that it is very early days for the science. The most interesting, most promising animal studies are only now beginning to be translated into clinical trials, and the process for approval of therapies takes many years and very few are likely to succeed.

Unfortunately, the public needs to be patient, but the good news is that potential treatments are progressing along the pipeline.

What are some examples of proven stem cell therapies?

For the last 50 years or so, there have been countless patients successfully treated with hematopoietic stem cells, commonly known as bone marrow transplants. This remains the prototype for how a stem cell therapy can work. Other successful examples include corneal stem cell grafts for certain eye conditions, and skin grafts for burn victims.

There are efforts to see if stem cells could successfully treat diseases like Parkinson's and diabetes, particularly type 1 diabetes. There are clinical trials testing whether stem cell therapy might work against macular degeneration, a blinding disease that is very common as people age. There are also early stage clinical trials for nervous system disorders including stroke, spinal cord injury, and ALS (Lou Gehrigs disease).

All of these examples are still at a very early stage, where the primary goal is to make sure that the approaches are safe. To determine if they are effective will require large, well-controlled, relatively long-term clinical trials.

What will it take to advance stem cell therapy into more real treatments?

This is where basic research comes in. The field is evolving quickly, there's much to be done, and there's still a huge amount of promise in stem cell therapies down the road. But it's going to take a lot of very careful and very laborious research before we get there.

Read more here:
Stem Cell Therapy: What's Real and What's Not at California's For-Profit Clinics - UCSF News Services

Read More...

Shelter animals receive care at ISU College of Veterinary Medicine on their way to adoption News Service Iowa State University – Iowa State…

November 2nd, 2019 12:45 am

AMES, Iowa In the real world, win-win scenarios are rare and often too good to be true. But the Iowa State University College of Veterinary Medicine has pulled off an even more elusive win-win-win by providing health care to thousands of shelter animals on their way to being adopted.

ISU veterinary students win by getting experience treating live animals, and animal shelters win by saving money through the free program. The biggest winners in the equation, however, are the shelter animals, who receive a clean bill of health and usually end up being adopted into loving homes.

The ISU College of Veterinary Medicine offers a surgery, anesthesia and community outreach course as a semester-long program for third-year veterinary students, with an option for extending the course for an additional semester. Students in the course gain hands-on experience admitting patients, screening them for a wide range of health problems and performing common procedures on the animals, such as spays and neuters.

Were helping the shelters move animals through their program so their length of stay is decreased, said Dr. Joyce Carnevale, a clinical assistant professor of veterinary clinical sciences who coordinates the community outreach portion of the program. A dog or cat that receives care in our program can get adopted more readily.

More than 300 animals, mostly cats and dogs, receive care over the course of a semester. Since the program began in 2016, more than 2,000 animals from more than 20 shelters, welfare organizations and animal rescues have gone through the program. The animals come not only from Iowa but Texas, Illinois, Missouri and beyond. And nearly all of the animals that receive care through the program wind up getting adopted, said Dr. Tamara Swor, a clinical assistant professor of veterinary clinical sciences who leads the surgery and anesthesia portions of the program.

From left, third-year veterinary medicine students Sami Naberhaus, Katie Griger and Monique Reid tend to George, a boxer-heeler mix, in the recovery room following surgery. Photo by Christopher Gannon. Larger image.

On a recent afternoon in early October, a frenzy of activity unfolded in three different rooms inside the ISU College of Veterinary Medicine. In an exam room, veterinary students checked in and performed routine health screenings on several dogs. These routine procedures include blood draws and heartworm checks on dogs older than six months. Its the first step in a process that takes five or six days during which every animal that enters the program undergoes a comprehensive health assessment, Carnevale said. The program treats all common problems presented in shelter pets, including eye, ear and skin problems and gastrointestinal parasites, she said.

A few rooms over, eight surgical teams prepared dogs to be neutered. Each team consisted of three students: a lead surgeon, an assistant surgeon and an anesthesiologist. The surgical teams rotate roles throughout the semester, ensuring each student gets a well-rounded experience. The students performed pre-operation checks on the dogs and anesthetized them, giving the animals comforting pats, rubs and ear scratches to put them at ease as much as possible.

Once a surgical team successfully anesthetized their dog, they wheeled the animal next door into an operating room with more than a dozen surgical stations. Each station comes equipped with individual monitors that offer constant updates on the patients vitals, as well as individual anesthesia machines. The surgeons scrubbed in to ensure everything remained sterile and then began their procedures.

Over the next hour or so, the student surgical teams completed their procedures to the steady beeps of the monitors. ISU veterinary faculty roamed the operation room, fielding occasional questions from students and monitoring the procedures.

Clinical assistant professor Joyce Carnevale holds Ernie, a shelter dog, while other dogs are prepared for surgery by third-year veterinary students at the ISU College of Veterinary Medicine. Photo by Christopher Gannon. Larger image.

DaKota Tilleraas, a third-year veterinary student from Hastings, Minnesota, said the program helps students develop skills theyll need as practicing vets. The physical exams, spays and neuters that make up a large portion of the semesters clinical work are the bread and butter of practicing veterinarians, Tilleraas said, and getting experience on live animals benefits the students immensely.

Earlier this semester, as Tilleraas prepared to perform her first spay as a surgeon on a cat, she learned one of her classmates had adopted the animal. That first procedure causes many students anxiety, and Tilleraas said she felt even more tension knowing her classmate would take the cat home.

So that was a little more pressure for me getting to do my first spay and then knowing shes already adopted by one of my classmates, Tilleraas said.

But the procedure went smoothly and her classmate was pleased with the results, Tilleras said.

Aislinn Ophoff, a third-year veterinary student from Terre Haute, Indiana, said her first spay on a cat went smoothly as well. So did her work as an anesthetist for a neuter, also on a cat. She said the course gives students a chance to work with cats and dogs of varying breeds, sizes and temperaments, mirroring the experiences of practicing veterinarians.

This is really helpful in giving us just the hands-on skills, clinical experience that you dont get when youre sitting in a classroom from nine to five, Ophoff said.

Ophoff also said she appreciated being able to perform the procedures under the watchful eye of faculty, who offer feedback and constructive criticism that helps the students improve.

The animal shelters benefit from the program as well, said Julie Taylor, shelter manager of the PAWS Humane Society in Charles City, which has sent animals to Iowa State for years. Taylor said the animals shes seen go through the ISU program have all received high-quality care. And the comprehensive nature of the program, from preventive health screenings to blood tests to spays and neuters all free of charge saves money for shelters and gives prospective pet owners peace of mind.

Its great to have all those details on an animal taken care of, and then at no cost. Thats huge, Taylor said.

More here:
Shelter animals receive care at ISU College of Veterinary Medicine on their way to adoption News Service Iowa State University - Iowa State...

Read More...

WARF donates $15 million to expand UW School of Veterinary Medicine – The Badger Herald

November 2nd, 2019 12:45 am

The Wisconsin Alumni Research Foundation recently donated $15 million for expanding the current University of Wisconsin School of Veterinary Medicine.

The expansion comes after six years of planning, according to Mark Markel, the Dean of the School of Veterinary Medicine.

SVM was built 35 years ago. About four years ago, the class size of the veterinary school increased from 80 to 96. When the next years incoming class is admitted, SVM will be fully expanded in terms of student capacity, leading to severe space constraints, Markel said.

Previously, the UW Veterinary Care clinics saw about 12,000 patients a year. Now, they see 28,000, leading to severe overcrowding, Markel said.

Rachel McNally, UW veterinary medical student, said the facility doesnt have the capacity to treat as many patients as they would like to.

UW claims Apple violated patent, US Supreme Court declines to hear caseThe U.S. Supreme Court declined to hear a patent case filed by the University of Wisconsin against Apple on Monday. Read

Its great that we have this expansion so we can reach more of our clientele and provide them with better care, McNally said.

Markel said the current space places constraints on teaching and learning spaces, and the new building will allow improvement on those items, particularly the hospital but also conference rooms.

Diana Lewis, UW veterinary medical student, said current students wont get to experience the immediate benefits of the expansion, but is excited for future students who will benefit.

I am really excited [because] we are super cramped for space here, Lewis said.

About five years ago, SVM conducted a feasibility study to determine the need for a new building across the street, Markel said.

SVM worked with legislators, campus leadership, University system leadership and Gov. Tony Evers in regards to this project. July 3, SVM was granted $90 million and needed to raise another $38 million. Previously, the school raised between $25 and $26 million, and the addition of the WARF gift of $15 million puts the SVM over the $38 million they had to raise, Markel said.

The equipment the building is going to require is expected to be an additional $10 million, according to a UW News article.

According to Markel, the project received $90 million in state funding, SVM raised about $25 million and WARF donated $15 million, with the project budget about $128 million.

Construction is set to begin in Spring 2021 and is projected to be completed in two years. Renovations of the current building will be completed by 2024, according to UW News.

The Small Animal Clinic will be expanded on the first floor and will be double the size it currently is. The Morrie Waud Large Animal Hospital will be remodeled, including a new cover arena and large animal isolation facility. The second floor will be a laboratory, conference rooms, graduate student offices and faculty offices. Markel said the third floor will be an infectious disease research space.

Make your own path: Panel of food-based executives offer advice to beginning entrepreneursAs part of the Wisconsin Alumni Research Foundations Entrepreneurons series, WARF hosted three food-based entrepreneurs in a panel to discuss Read

The parking ramp on Observatory is under construction because the workers cant build unless space is available for parking. Veterinary students, like Lewis, claim parking space constraints often provide various difficulties other than not having a place to park a car.

Its a stressor for people. Sometimes people bring in dogs or bigger animals that cant walk. We do have carts that can get them into the building but there is a little bit of a strain there, Lewis said.

SVM experienced severe equipment shortages over the years. The original building did not have MRI units and CT scanners in the clinics. The clinic was able to fit a CT scanner but it cannot be easily accessed. The MRI unit is in a trailer outside, Markel said.

To get our animals scanned and on the MRI unit we have to anesthetize them in this building take them through about a hundred yards of corridors outside, so in the winter thats through snow, Markel said.

During the remodel, the MRI unit will be brought inside. The clinic pathology department will move into the new building, freeing up space in the current building. That space will likely accommodate the cancer center due to the large number of patients seen each year, Markel said.

Exam rooms have sign up sheets because there are not enough exam rooms available for the amount of appointments. There are only three computers in the neurology ward which makes looking up records or information about clients and patients in a timely manner difficult, said McNally and Lewis.

The surgery suite also has space constraints. When teaching about radiographs or diagnostics, faculty and students are huddled around one computer said Lewis and McNally.

Its hard to learn under current space conditions, McNally said.

Clients and patients have also been affected by these space constraints.

Sometimes you have to wait multiple months to get the initial patient appointment because they can only see so many patients in a day, Lewis said. I am amazed that we can fit as many appointments in a day that we can.

There is a push to teach students and faculty how to make the clinic a comfortable space for pets and clients, they said, which can often be difficult with the high volume of patients and minimal space.

McNally said there should be an area in the new building to for pets to relax and quieter places for them to recover after procedures.

Its really hard to be a fear free space when there is so much noise and so much going on because were such a busy facility, McNally said.

The WARF gift will buy new equipment, but students like McNally are excited about the little things such as chairs, computers and phones that will improve the quality of patient care.

The current building does not have many windows or courtyard spaces, McNally said, and this can affect the mental health of the clients and patients. The new building will have plenty of these additions.

Little things can make our ability to provide care that much easier and that much higher quality that it can make such a huge difference, McNally said.

Continue reading here:
WARF donates $15 million to expand UW School of Veterinary Medicine - The Badger Herald

Read More...

Canine cancer screening test in the works – VeterinaryPracticeNews.com

November 2nd, 2019 12:45 am

Suggested Veterinary Products

Dentistry, Food & Nutrition

Veterinarians may soon be equipped with a tool that would assist in the early detection of canine cancer.

Veterinary oncologists at the Texas A&M College of Veterinary Medicine & Biomedical Sciences (CVM) are set to begin testing Nu.Q by VolitionRx, a suite of routine blood tests for the unique nucleosomes that serve as biomarkers in cancer.

The goal of this project with Volition is to provide all veterinarians with simple, affordable, routine blood tests that can help identify disease early and improve the lives of both animals and the people who love them, says Eleanor M. Green, DVM, Dipl. ACVIM, Dipl. ABVP, the Carl B. King dean of veterinary medicine.

The research will be led by Heather Wilson-Robles, DVM, DACVIM, associate professor and Fred and Vola N. Palmer chair in comparative oncology at the CVM.

I am excited to be working with Volition on this project, Dr. Wilson-Robles says. The Nu.Q platform has the potential to change the landscape of veterinary cancer diagnostics and provide much needed affordable and reliable screening tests that, to date, simply dont exist in the veterinary world.

Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life, Texas A&M says, adding that 25 percent of the more than 55 million dogs in the U.S. are expected to develop cancer at some stage of their life.

Visit link:
Canine cancer screening test in the works - VeterinaryPracticeNews.com

Read More...

Page 830«..1020..829830831832..840850..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick